E. Ohman J or Asset Management AB Sells 2,700 Shares of Natera, Inc. $NTRA

Key Points

• E. Ohman J or Asset Management AB sold 2,700 shares of Natera, Inc., reducing its stake by 8.6% and leaving them with 28,563 shares worth approximately $4.8 million.
• Insider trading activity included the CFO selling 3,045 shares and the CEO selling 6,092 shares, indicating a decrease in ownership for both executives.
• Equities analysts have a positive outlook on Natera with an average target price of $194.00 and multiple analysts rating it as a "Buy".

E. Ohman J or Asset Management AB trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 8.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 28,563 shares of the medical research company's stock after selling 2,700 shares during the period. E. Ohman J or Asset Management AB's holdings in Natera were worth $4,825,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Bank of Jackson Hole Trust bought a new position in shares of Natera during the 1st quarter valued at $29,000. Rakuten Securities Inc. lifted its holdings in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after buying an additional 119 shares during the period. ORG Partners LLC bought a new position in Natera in the 1st quarter worth $32,000. TCTC Holdings LLC raised its holdings in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock worth $33,000 after purchasing an additional 106 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total transaction of $500,310.00. Following the completion of the transaction, the insider owned 130,205 shares in the company, valued at $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 6,092 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $139.81, for a total value of $851,722.52. Following the transaction, the chief executive officer owned 169,400 shares of the company's stock, valued at $23,683,814. This trade represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,423 shares of company stock valued at $8,459,656 in the last quarter. 5.63% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Barclays reaffirmed an "overweight" rating and issued a $210.00 target price (up from $190.00) on shares of Natera in a report on Friday, August 8th. Royal Bank Of Canada set a $268.00 target price on Natera and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a report on Monday, July 28th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $194.00.

Natera Stock Performance

NASDAQ:NTRA traded up $1.35 during trading hours on Friday, reaching $181.21. The stock had a trading volume of 253,334 shares, compared to its average volume of 1,446,821. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00. The company has a 50 day moving average price of $156.38 and a two-hundred day moving average price of $154.77. The stock has a market capitalization of $24.87 billion, a PE ratio of -94.85 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company's revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.